8-K: Precision BioSciences Receives Clinical Trial Approval in Moldova for Hepatitis B Treatment

Precision BioSciences has received its first clinical trial application approval in Moldova for its PBGENE-HBV program, a gene editing therapy for chronic hepatitis B.

Summary

• Precision BioSciences has announced that it has received clinical trial application (CTA) clearance in Moldova for its lead candidate, PBGENE-HBV, for the treatment of chronic hepatitis B.
• The company expects to report approximately $121 million in cash, cash equivalents, and restricted cash as of September 30, 2024.
• PBGENE-HBV is the first in vivo gene editing program for chronic hepatitis B virus to move into global clinical trials.
• The company is moving towards dosing patients in the Phase 1 clinical program.
• Precision BioSciences is pursuing additional CTA and IND approvals globally.
• The company plans to provide an update on the PBGENE-HBV program on November 15th before the American Association for the Study of Liver Diseases (AASLD) Annual Meeting.
• An estimated 300 million people globally have chronic hepatitis B infection, with current treatments not providing a functional cure.

Sentiment

Score: 8

Explanation: The document is very positive due to the clinical trial approval and the potential of the therapy. However, there are still risks associated with clinical development and funding.

Positives

• The CTA approval in Moldova is a significant milestone for the company's transition to a clinical-stage in vivo gene editing company.
• PBGENE-HBV has the potential to achieve a functional cure for chronic hepatitis B, unlike current treatments.
• The company has a robust regulatory package highlighting the safety and antiviral effects of PBGENE-HBV.
• The company is leveraging its expertise in hepatitis B to advance PBGENE-HBV towards dosing the first patient.
• The ARCUS platform is a novel and proprietary gene editing platform with unique characteristics.

Negatives

• The cash balance of $121 million is an unaudited and preliminary estimate.
• The review of the company's financial statements for the quarter ended September 30, 2024, is ongoing and could result in changes to the reported cash balance.
• The company is still in the early stages of clinical development and faces risks associated with clinical trials and regulatory approvals.

Risks

• The company's ability to procure sufficient funding or other partnership opportunities to advance its programs is a risk.
• The progression and success of the company's programs and product candidates are uncertain.
• There is a risk that other genome-editing technologies may provide significant advantages over the company's ARCUS technology.
• The company's ability to assess the safety and efficacy of its product candidates is limited.
• The company faces risks associated with clinical trials, regulatory approvals, and manufacturing.

Future Outlook

The company plans to pursue additional CTA and IND approvals globally and is focused on rapidly enrolling patients into the study and generating robust clinical data. They will provide updates as they receive additional regulatory approvals and plan to share more information about the Phase 1 program on November 15th.

Management Comments

• 'With rapid regulatory approval in hand, we are working diligently to screen and dose patients at our first clinical site in Moldova,' said Michael Amoroso, Chief Executive Officer of Precision BioSciences.
• 'We are thrilled to receive CTA approval in Moldova given the high prevalence of chronic hepatitis B in the country and their expertise gained from multiple Phase 1 clinical trials in hepatitis B,' added Dr. Murray Abramson, Senior Vice President, Head of Clinical Development of Precision BioSciences.

Industry Context

This announcement is significant as it represents a major step forward in the development of gene editing therapies for chronic hepatitis B, a disease with limited curative options. The company's approach of targeting cccDNA is novel and could potentially offer a functional cure, which is a major unmet need in the field.

Comparison to Industry Standards

• Current standard of care for chronic hepatitis B involves daily treatment with nucleos(t)ide analogs, which only offer a 1-3% chance of functional cure, highlighting the potential of PBGENE-HBV.
• Other companies like Gilead Sciences and Vir Biotechnology are also working on hepatitis B treatments, but Precision's approach of directly targeting cccDNA with gene editing is a unique approach.
• The company's ARCUS platform is differentiated from other gene editing technologies like CRISPR-Cas9 due to its smaller size and simpler structure, which may lead to more precise and efficient gene editing.

Stakeholder Impact

• Shareholders will likely view the clinical trial approval positively.
• Patients with chronic hepatitis B may benefit from this potential new treatment.
• Employees of Precision BioSciences will be involved in the clinical development of PBGENE-HBV.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• The company will screen and dose patients at its first clinical site in Moldova.
• The company will pursue additional CTA and IND approvals globally.
• The company will provide an update on the PBGENE-HBV program on November 15th.
• The company will continue to develop its ARCUS gene editing platform.

Key Dates

Keywords

gene editing, hepatitis B, PBGENE-HBV, clinical trial, ARCUS platform, in vivo, regulatory approval, cccDNA, biotechnology, liver disease